The common wisdom over the past few years is that biotechs are having a rough time attracting venture capital financing thanks to changing priorities for exit strategies and the vagaries in successful drug development and approval. A new analysis, though, suggests that perhaps a shift may be under way - biopharma VC financing totaled nearly $3.5 billion last year, a gain of almost 16 percent over 2010.
Most of that increase occurred in the fourth quarter, when there were 41 deals and financing amounted to $825 million, a 90 percent jump from the last quarter of 2010, when there were 28 deals according to OnBioVC, a research firm that tracks venture capital doings. Overall, there were 160 deals in 2011, compared with 153 during the year before.
To read the full, original article click on this link: Biotechs Got How Much Venture Capital Money? // Pharmalot
